A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients.

Background: There are no studies performed in India on the safety of highly active antiretroviral therapy (HAART) combinations which focus on the base-line CD4+ T-cell count. Further, no data on risk factors for Adverse drug reactions (ADRs) to HAART and there is a lack of data on CD4+ T-cell count recovery after HAART.

Objectives: The aim of this study was to assess risk factors for ADRs to HAART.